We’d love to hear your feedback on this activity. It helps us to continually improve our products.
To further understand the key developments and research presented in the field of gynaecological oncology at ESMO 2023, we spoke with Dr Domenica Lorusso, Professor of Obstetrics and Gynaecology at the Fondazione Policlinico Universitario Agostino Gemelli – UCSC Italy. In our interview, Dr Lorusso discuses the findings and clinical impact of two stand out trials; […]
This July, the PrEvCan campaign is dedicated to raising awareness about women’s cancer risk in connection with breastfeeding and hormone replacement therapy (HRT). Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of […]
The relationship between breastfeeding and a reduction in cancer risk is the focus of the PrEvCan Campaign, this July. Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of cancer. In this interview […]
The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]
Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for […]
Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study. Watch Dr Keiichi Fujiwara’s interview at ESMO 2022, on the Phase 3 GOTIC-002 LUFT study results – chemotherapy with tegafur-uracil for locally advanced cervical […]
The phase 3 MITO23 trial investigated trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients Dr Domenica Lorusso (Fondazione IRCCS National Cancer institute of Milan, Milan, Italy) discusses the rationale for the trial, trabectedin’s mode of action, the phase 3 results, […]
We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. The abstract ‘Safety and efficacy of vibostolimab (vibo) plus […]
touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective […]
Get the latest clinical insights from touchONCOLOGY